Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

Myriad Genetics, Inc. (MYGN) is driving innovation across Oncology, Women's Health and Pharmacogenomics, and heavily invests in labs and digital capabilities. Thecompany’s Oncology growth strategy centers on the expansion of companion diagnostics, market expansion through new clinical guidelines and the introduction of new offerings. In addition, key partnerships, such as with GSK and QIAGEN, underscore its commitment to improving access to HRD diagnostic testing. Yet, a volatile macroeconomic situation and ...